receptor blockers (ARBs), and improve prognosis in CKD patients. Inhibition of 23 endothelin (ET) system in combination with established RAASis may represent such an 24 approach. There are complex interactions between both systems and similarities in their 25 renal physiologic and pathophysiologic actions that provide theoretical rationale for 26 combined inhibition. This view is supported by some experimental studies in models of 27 both diabetic and non-diabetic CKD showing that a combination of RAASis with ET 28 receptor antagonists (ERAs) ameliorate proteinuria, renal structural changes and 29 molecular markers of glomerulosclerosis, renal fibrosis or inflammation more effectively 30 than RAASis or ERAs alone. Practically all clinical studies exploring the effects of 31
RAASis and ERAs combination in nephroprotection have thus far applied add-on 32 designs, in which an ERA is added to baseline treatment with ACEIs or ARBs. These 33 studies, conducted mostly in patients with diabetic nephropathy, have shown that ERAs 34 effectively reduce residual proteinuria in patients with baseline RAASis treatment. term studies are currently being conducted to determine whether promising 36
Introduction 41
Inhibition of the renin-angiotensin-aldosterone system (RAAS) plays a pivotal 42 role in treatment of chronic kidney diseases (CKD). Inhibitors of the RAAS (RAASis) 43 can slow the progressive decrease in glomerular filtration rate (GFR), reduce proteinuria 44 and cardiovascular mortality and morbidity in both diabetic and non-diabetic proteinuric 45 kidney diseases. However, despite documented beneficial effects of RAASis, reversal of 46 the course of progressive forms of CKD or at least long-term stabilization of renal 47 diuretic actions (26, 55) . 156
157
Most of the evidence suggests that ET B is the main receptor responsible for 158 natriuretic actions of ET-1. However, observations in mice with double ET A /ET B 159 knockout in the CD, which display more severe hypertension than ET B KO mice indicate 160 a contribution of ET A to ET-1-induced natriuresis (reviewed in (42) ). This is further 161 supported by the fact that edema, fluid retention or even heart failure complicate clinical 162 use of the selective ET A receptor antagonists (ERAs) (50). 163
164

Interactions and cross-talk between RAAS and ET-1 165
In addition to similarities in some actions of ET-1 and effectors of RAAS in the 166 pathophysiology of kidney diseases, there are complex interactions and cross-talk 167 between both systems. Angiotensin II stimulates ET-1 release and expression in a variety 168 of cell types including renal cells (23, 24, 43 In contrast to the effects of ET-1 on AngII and aldosterone, ET-1 appears to inhibit 183 release of renin. Endothelin-1 inhibits renin release from isolated juxtaglomerular 184 apparatus (51, 60). In vivo, low doses of ET-1 that do not produce any significant changes 185 in total peripheral resistance also reduce renin release as observed in anesthetized dogs 186 (49, 57). Higher doses of ET-1 that increase BP increase plasma renin activity (57). The RADAR trial (18) that followed has been thus far the largest and best 307 documented study assessing dual blockade in proteinuric CKD. The study tested 308 atrasentan at 0.75 and 1.25 mg/d, and did not include the highest dose from the previous 309 study (41), in 211 Type 2 diabetic patients with albuminuria (albumin/creatinine ratio 310 (ACR) 500-3500 mg/g) and eGFR within the 30-75 ml/min range treated with maximally 311 tolerated baseline ACEIs or ARBs. In contrast to placebo, both doses of atrasentan were 312 effective in reducing residual albuminuria by about 40%. There was mild increase in 313 body weight, but not in prevalence of edema and the treatment was in general well 314
tolerated. 315
In both studies, atrasentan also reduced BP. This modest add-on effect of 316 atrasentan on BP can hardly explain impressive effects on residual proteinuria. On the 317 other hand, rapid return of albuminuria after drug withdrawal (as observed in the 318 atrasentan studies) suggests contribution of the hemodynamic mechanism to the 319 antiproteinuric effect, in accord with a previous report by Dhaun et al (20) 
